Clinical Trial Update: A Clinical Trial Evaluating the Safety and Efficacy of Myelin-peptide Loaded tolDC as Treatment for MS [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating myelin-peptide loaded tolerogenic dendritic cells for multiple sclerosis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Myelin-peptide Loaded tolDC

Snippet

Sponsor: University Hospital, Antwerp | Conditions: Multiple Sclerosis | Phase 2 | Status: WITHDRAWN